NDLI: Triple Therapy with Darbepoetin Alfa, Idebenone, and Riboflavin in Friedreich’s Ataxia: an Open-Label Trial

Content Provider	Springer Nature Link
Author	Arpa, Javier Sanz Gallego, Irene Rodríguez de Rivera, Francisco J. Domínguez Melcón, Francisco J. Prefasi, Daniel Oliva Navarro, Javier MoreYangüela, Mar Pascual Pascual, Samuel I.
Copyright Year	2013
Abstract	Minimal objective evidence exists regarding management of Friedreich’s ataxia (FRDA). Antioxidant and recombinant human erythropoietin therapies have been considered potential treatments to slow progression of FRDA in a small number of studies. The primary objective of the current study was to test the efficacy, safety, and tolerability of triple therapy—darbepoetin alfa, idebenone, and riboflavin—in FRDA in a clinical pilot study. Patients included in this study were nine females, 16 to 45 years of age (average 28 ± 8), diagnosed with FRDA with confirmed GAA repeat expansion mutations in the FXN gene and a GAA repeat ≥400 on the shorter allele. Patients had a baseline score between 8 and 28.5 (average 20.7 ± 8.3) on the scale for the assessment and rating of ataxia and 94.3 ± 27.2 g/m$^{2}$ in left ventricular mass index (LVMI). Patients had been treated with triple therapy with 150 μg darbepoetin alfa every 2 or 3 weeks, 10–20 mg/kg/day idebenone, and 10–15 mg/kg/day riboflavin for 32 ± 19.4 months (range of 8–56 months). Triple therapy was tolerated. Although not statistically significant, improvement of ataxia was observed during the first six 4-month periods of the study. Furthermore, a small decrease in disease progression during the first 2 years of treatment was observed. Long-term statistically nonsignificant improvement of LVMI and stability of the echocardiographic parameters could be considered. Triple therapy may slow disease progression of FRDA.
Starting Page	713
Ending Page	720
Page Count	8
File Format	PDF
ISSN	14734222
Journal	The Cerebellum
Volume Number	12
Issue Number	5
e-ISSN	14734230
Language	English
Publisher	Springer US
Publisher Date	2013-04-27
Publisher Place	Boston
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Friedreich’s ataxia Darbepoetin alfa Idebenone Riboflavin Cardiomyopathy Neurosciences Neurology Neurobiology
Content Type	Text
Resource Type	Article
Subject	Neurology Neurology (clinical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Combined Therapy with Idebenone and Deferiprone in Patients with Friedreich’s Ataxia

Iron and iron-responsive proteins in the cardiomyopathy of Friedreich’s ataxia

Spinal Cord Atrophy Correlates with Disability in Friedreich’s Ataxia

Routine Clinical Testing Underestimates Proprioceptive Deficits in Friedreich’s Ataxia

Superior Cerebellar Peduncle Atrophy in Friedreich’s Ataxia Correlates with Disease Symptoms

PPAR-γ Agonist Azelaoyl PAF Increases Frataxin Protein and mRNA Expression. New Implications for the Friedreich’s Ataxia Therapy

Friedreich’s Ataxia: From the (GAA)$_{ n }$ Repeat Mediated Silencing to New Promising Molecules for Therapy

Neuroanatomical Correlates of Depression in Friedreich’s Ataxia: a Voxel-Based Morphometry Study

Restless Legs and Substantia Nigra Hypoechogenicity are Common Features in Friedreich’s Ataxia

Triple Therapy with Darbepoetin Alfa, Idebenone, and Riboflavin in Friedreich’s Ataxia: an Open-Label Trial

Similar Documents

Combined Therapy with Idebenone and Deferiprone in Patients with Friedreich’s Ataxia

Iron and iron-responsive proteins in the cardiomyopathy of Friedreich’s ataxia

Spinal Cord Atrophy Correlates with Disability in Friedreich’s Ataxia

Routine Clinical Testing Underestimates Proprioceptive Deficits in Friedreich’s Ataxia

Superior Cerebellar Peduncle Atrophy in Friedreich’s Ataxia Correlates with Disease Symptoms

PPAR-γ Agonist Azelaoyl PAF Increases Frataxin Protein and mRNA Expression. New Implications for the Friedreich’s Ataxia Therapy

Friedreich’s Ataxia: From the (GAA)$_{ n }$ Repeat Mediated Silencing to New Promising Molecules for Therapy

Neuroanatomical Correlates of Depression in Friedreich’s Ataxia: a Voxel-Based Morphometry Study

Restless Legs and Substantia Nigra Hypoechogenicity are Common Features in Friedreich’s Ataxia

Triple Therapy with Darbepoetin Alfa, Idebenone, and Riboflavin in Friedreich’s Ataxia: an Open-Label Trial